¾«¶«Ó°Òµ

Reporting on their study with lab-grown human cells, researchers at The Johns Hopkins University and the University of Maryland say that blocking a second blood vessel growth protein, along with one that is already well-known, could offer a new way to treat and prevent a blinding eye disease caused by diabetes.

ÌýA summary of the study appears online May 25 inÌýProceedings of the National Academy of Sciences.

The disease, diabetic retinopathy, is the most common cause of vision loss in working-age adults in the United States. Diabetic eye disease occurs when the normal blood vessels in the eye are replaced over time with abnormal, leaky, fragile blood vessels that leak fluid or bleed into the eye, damaging the light-sensitive retina and causing blindness. Forty to 45 percent of ¾«¶«Ó°Òµns with diabetes have diabetic retinopathy, according to the National Eye Institute.

Laser-sealing eye blood vessels can save central vision, but this often sacrifices peripheral and night vision, according toÌý, an assistant professor of ophthalmology at the Johns Hopkins University School of Medicine. Several recently developed drugs — bevacizumab, ranibizumab and aflibercept — can help treat these blood vessels by blocking the action of VEGF, a so-called growth factor released as part of a chain of signals in response to low oxygen levels, which stimulates the growth of new, often abnormal, blood vessels. But studies have shown that although these drugs slow progression to proliferative diabetic retinopathy, it does not reliably prevent it.Ìý

Donate to Nonprofits Supporting Diabetes Research:

• Diabetes Research and Wellness Foundation
• Diabetes National Research Group
• Diabetes Research Institute Foundation, Inc.